This issue of Hematology/Oncology Clinics is edited by Dr. Jennifer Brown and focuses on Chronic Lymphocytic Leukemia. Article topics include: What Have Recent Genomic Advances Taught us About CLL?, Biology of CLL in Different Microenvironments,What is the Significance of Stereotyped BCRs in CLL?, Understanding Immunodeficiency in CLL, MBL vs CLL: How Important is the Distinction?, Risk Stratification of CLL in 2012, Minimal Residual Disease Measurement in CLL, The BTK Inhibitor PCI-32765 in CLL, and Evolving Role of Stem Cell Transplantation in CLL.
1. Cover image - p. 1 2. Title page - p. 2 3. Table of Contents - p. 3 4. Contributors - p. 4 5. Forthcoming Issues - p. 5 6. Preface - p. 6 7. Genomic Approaches to Chronic Lymphocytic Leukemia - p. 7 8. Biology of Chronic Lymphocytic Leukemia in Different Microenvironments - p. 14 9. Understanding the Immunodeficiency in Chronic Lymphocytic Leukemia - p. 36 10. The Significance of Stereotyped B-Cell Receptors in Chronic Lymphocytic Leukemia - p. 54 11. MBL Versus CLL - p. 62 12. The Role of Minimal Residual Disease Measurements in the Therapy for CLL - p. 71 13. 17p Deletion in Chronic Lymphocytic Leukemia - p. 80 14. Improving the Treatment Outcome of Patients with Chronic Lymphocytic Leukemia Through Targeted Antibody Therapy - p. 87 15. Phosphoinositide 3′-Kinase Inhibition in Chronic Lymphocytic Leukemia - p. 97 16. Chimeric Antigen Receptor Therapy for Chronic Lymphocytic Leukemia - p. 103 17. The Evolving Role of Stem Cell Transplantation in Chronic Lymphocytic Leukemia - p. 110 18. Index - p. 117
No hay muestra disponible
No hay ficha técnica disponible
This issue of Hematology/Oncology Clinics is edited by Dr. Jennifer Brown and focuses on Chronic Lymphocytic Leukemia. Article topics include: What Have Recent Genomic Advances Taught us About CLL?, Biology of CLL in Different Microenvironments,What is the Significance of Stereotyped BCRs in CLL?, Understanding Immunodeficiency in CLL, MBL vs CLL: How Important is the Distinction?, Risk Stratification of CLL in 2012, Minimal Residual Disease Measurement in CLL, The BTK Inhibitor PCI-32765 in CLL, and Evolving Role of Stem Cell Transplantation in CLL.
1. Cover image - p. 1 2. Title page - p. 2 3. Table of Contents - p. 3 4. Contributors - p. 4 5. Forthcoming Issues - p. 5 6. Preface - p. 6 7. Genomic Approaches to Chronic Lymphocytic Leukemia - p. 7 8. Biology of Chronic Lymphocytic Leukemia in Different Microenvironments - p. 14 9. Understanding the Immunodeficiency in Chronic Lymphocytic Leukemia - p. 36 10. The Significance of Stereotyped B-Cell Receptors in Chronic Lymphocytic Leukemia - p. 54 11. MBL Versus CLL - p. 62 12. The Role of Minimal Residual Disease Measurements in the Therapy for CLL - p. 71 13. 17p Deletion in Chronic Lymphocytic Leukemia - p. 80 14. Improving the Treatment Outcome of Patients with Chronic Lymphocytic Leukemia Through Targeted Antibody Therapy - p. 87 15. Phosphoinositide 3′-Kinase Inhibition in Chronic Lymphocytic Leukemia - p. 97 16. Chimeric Antigen Receptor Therapy for Chronic Lymphocytic Leukemia - p. 103 17. The Evolving Role of Stem Cell Transplantation in Chronic Lymphocytic Leukemia - p. 110 18. Index - p. 117
No hay muestra disponible
No hay ficha técnica disponible
